Roche Obesity Study Data Look Encouraging -- Market Talk

Dow Jones01-27

0751 GMT - Roche released data from a midstage study of its weight-loss drug candidate CT-388 that looks encouraging, Vontobel's Stefan Schneider says in a research note. The Swiss pharmaceutical company said CT-388 achieved a statistically significant weight loss of 22.5% at week 48 without reaching a weight-loss plateau, suggesting the drug worked in a phase 2 clinical trial, the analyst says. The drug candidate was one of the assets Roche acquired through its deal for Carmot Therapeutics in late 2023 to build a cardiometabolic portfolio and the company has since then achieved several milestones in its effort, the analyst adds. Vontobel expects Roche to launch the drug in 2028 at the earliest and estimates it could generate peak sales of 2.5 billion Swiss francs. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

January 27, 2026 02:52 ET (07:52 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2606206437?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-27 15:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606206437","market":"nz","top_or_hot":-1,"title":"Roche Obesity Study Data Look Encouraging -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0751 GMT - Roche released data from a midstage study of its weight-loss drug candidate CT-388 that looks encouraging, Vontobel's Stefan Schneider says in a research note. The Swiss pharmaceutical company said CT-388 achieved a statistically significant weight loss of 22.5% at week 48 without reaching a weight-loss plateau, suggesting the drug worked in a phase 2 clinical trial, the analyst says. The drug candidate was one of the assets Roche acquired through its deal for Carmot <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> in late 2023 to build a cardiometabolic portfolio and the company has since then achieved several milestones in its effort, the analyst adds. Vontobel expects Roche to launch the drug in 2028 at the earliest and estimates it could generate peak sales of 2.5 billion Swiss francs. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 27, 2026 02:52 ET (07:52 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche Obesity Study Data Look Encouraging -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche Obesity Study Data Look Encouraging -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-27 15:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0751 GMT - Roche released data from a midstage study of its weight-loss drug candidate CT-388 that looks encouraging, Vontobel's Stefan Schneider says in a research note. The Swiss pharmaceutical company said CT-388 achieved a statistically significant weight loss of 22.5% at week 48 without reaching a weight-loss plateau, suggesting the drug worked in a phase 2 clinical trial, the analyst says. The drug candidate was one of the assets Roche acquired through its deal for Carmot <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> in late 2023 to build a cardiometabolic portfolio and the company has since then achieved several milestones in its effort, the analyst adds. Vontobel expects Roche to launch the drug in 2028 at the earliest and estimates it could generate peak sales of 2.5 billion Swiss francs. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 27, 2026 02:52 ET (07:52 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03165","symbol_name":"华夏欧优股对冲","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2606206437","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2606206437","pubTimestamp":1769500320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0751 GMT - Roche released data from a midstage study of its weight-loss drug candidate CT-388 that looks encouraging, Vontobel's Stefan Schneider says in a research note. The Swiss pharmaceutical company said CT-388 achieved a statistically significant weight loss of 22.5% at week 48 without reaching a weight-loss plateau, suggesting the drug worked in a phase 2 clinical trial, the analyst says. The drug candidate was one of the assets Roche acquired through its deal for Carmot Therapeutics in late 2023 to build a cardiometabolic portfolio and the company has since then achieved several milestones in its effort, the analyst adds. Vontobel expects Roche to launch the drug in 2028 at the earliest and estimates it could generate peak sales of 2.5 billion Swiss francs. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03165":"华夏欧优股对冲","BK4007":"制药","RHHBY":"罗氏控股"},"translate_title":"罗氏肥胖研究数据看起来令人鼓舞——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"RHHBY":0.9},"content_text":"0751 GMT - Roche released data from a midstage study of its weight-loss drug candidate CT-388 that looks encouraging, Vontobel's Stefan Schneider says in a research note. The Swiss pharmaceutical company said CT-388 achieved a statistically significant weight loss of 22.5% at week 48 without reaching a weight-loss plateau, suggesting the drug worked in a phase 2 clinical trial, the analyst says. The drug candidate was one of the assets Roche acquired through its deal for Carmot Therapeutics in late 2023 to build a cardiometabolic portfolio and the company has since then achieved several milestones in its effort, the analyst adds. Vontobel expects Roche to launch the drug in 2028 at the earliest and estimates it could generate peak sales of 2.5 billion Swiss francs. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 27, 2026 02:52 ET (07:52 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2606206437","isCrawlerRequest":true}